Digitizing Healthcare – Embracing change. Creating opportunity.
Emily Wyatt
The future of healthcare is digital
For many industries, embracing digitization has become a matter of survival. Healthcare has always had a reputation of being resistant to change, but consumer demand and a rapidly evolving technology-driven world have led the digitization of healthcare to move at a frantic pace.
In comparison with other industries, healthcare has been slow to take advantage of the digital revolution. Traditionally healthcare has always been a difficult industry in which to innovate; it is highly regulated, expensive, complex and risk averse. However, rising drug development costs, increased patient expectations, and a growing dependence on health resources, place the industry under increasing pressure to move with the times. Many organizations with an interest in health, including the pharmaceutical industry, medical technology companies, health insurers, and payers are focusing on the digital world. However, the strongest digital health innovators are now coming in from outside the industry.
How tech companies are driving digital transformation
Healthcare represents an incredibly lucrative opportunity for traditional technology companies. The tech giants – Alphabet (the parent company of Google), Amazon, Apple, Microsoft and IBM – are taking the lead and heavily investing their time, resource and talent into healthcare.
Each of the major tech companies are using their core business strengths to create digital health initiatives across a variety of platforms. These are being implemented at every touchpoint of the patient/health professional journey ranging from data storage, artificial intelligence (AI), e-commerce, voice-enabled solutions, consumer apps and wearables. By developing tools that patients and health professionals embrace, and through collaborations with healthcare providers, the Big 5 are poised to reinvent the healthcare industry.
About the author
Emily Wyatt
Emily is a Senior Associate based in the London office. Since joining Deallus, Emily has lead research for top tier pharmaceutical clients supporting their global strategy to implement personalised healthcare initiatives across the value chain. She has also facilitated competitive simulation workshops looking at the impact of Tech disruption in healthcare. Emily has significant experience across a variety of therapeutic areas and industries including neuroscience, oncology, immune-oncology, companion diagnostics, liver diseases, autoimmune diseases and personalised healthcare.
Emily holds a MPhil in Bioscience Enterprise from the University of Cambridge and a BSc Honours in Biochemistry from the University of Bristol. Throughout her career, Emily has also developed strong expertise in the medical devices space, having led business development projects for medical device companies in oncology and inflammatory diseases.
You may also be interested in…
Episode 1: Navigating Market Disruption After COVID-19
Peter Hempshall, CEO of Deallus, is partnering with Rita Numerof, Founder & President of Numerof & Associates, for a discussion series centered on the lasting impact that COVID-19 will have on business models in the healthcare industry. Tune in to be part of a discussion on how the pandemic has accelerated key market shifts, how organizations will need to operate differently, and what solutions can be offered for successfully moving businesses forward in this new reality.
Yacine Amrani joins Deallus as Senior Principal
We are very pleased to welcome Yacine Amrani to our Deallus team as Senior Principal. Yacine brings a strong background in Market Access, pricing and U.S. Managed Markets including extensive payer, access, pricing and reimbursement capabilities. Yacine has led engagements across multiple therapeutic areas both in the U.S and overseas for leading pharma players as well as biotech firms.
COVID-19 – tracking the fast-moving landscape
As the COVID-19 pandemic continues to impact patients, healthcare systems, and global economic outlooks, we focus on the key considerations and strategies for pharma companies when the data generation for possible therapies is becoming increasingly complex to analyze. There are several COVID-19 treatment and vaccine databases containing an aggregation of publicly-available information from validated sources detailing treatments and vaccines currently in development.
COVID-19, China, and Telemedicine
As COVID-19 continues to disrupt normalcy across the globe, China is responding with innovation in online health delivery and telemedicine. How has China encouraged telemedicine uptake? What are the factors contributing to China’s relatively quick utilization of telemedicine in the face of COVID-19? And what learnings can we gain from taking a closer look? We explore these questions in our latest addition to our COVID-19+Pharma Series.
To learn more about this topic, or to find out about ways in which Deallus can help you, please get in touch.
For any questions or comments on this thought piece, please reach out to Julie Munch Khan – Deallus Chief Commercial Officer
